News Quantified

ONCY – oncolytics biotech inc. - common shares (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era [Canadian Business Journal (Canada)]

Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance [Globe and Mail, The (Toronto, Canada)]

GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era

Oncolytics Biotech (NASDAQ:ONCY) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.

Oncolytics Biotech® Reschedules Special Meeting of Shareholders to Change Jurisdiction of Incorporation to Nevada

-3.6%

MISS

-7.7%

BEAT

-3.4%

BEAT

-10.5%

MISS

Form EFFECT ONCOLYTICS BIOTECH INC

Form 6-K ONCOLYTICS BIOTECH INC For: Dec 09

Form 424B3 ONCOLYTICS BIOTECH INC

Form F-4/A ONCOLYTICS BIOTECH INC

Form 6-K ONCOLYTICS BIOTECH INC For: Nov 20

Top News Gainers

3/24 Oncolytics Biotech® Announces Favourable AWARE-1 Safety Update 33.3%

1/3 Form SUPPL ONCOLYTICS BIOTECH INC 17.3%

10/30 Breast Cancer Awareness Month Arrives With New Teamwork From Biotech Developers on the Way 17.2%

8/16 Form SUPPL ONCOLYTICS BIOTECH INC 15.6%

11/19 Oncolytics Biotech, Inc. (NASDAQ: ONCY) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. 14.5%

1/2 Oncolytics Biotech, Inc. (NASDAQ: ONCY) had its price target raised by analysts at Roth Capital from $6.80 to $9.00. They now have a "buy" rating on the stock. 13.8%

10/15 Oncolytics Biotech(R) Presents Clinical Data Highlighting the Effectiveness of Intravenous Delivery to and Replication of Pelareorep in Tumors 10.6%

3/19 Oncolytics Biotech, Inc. (NASDAQ: ONCY) had its "buy" rating re-affirmed by analysts at Canaccord Genuity. They now have a $300.00 price target on the stock. 10.0%

3/4 Oncolytics Biotech, Inc. (NASDAQ: ONCY) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. 8.7%

11/12 Form 6-K ONCOLYTICS BIOTECH INC For: Nov 12 8.1%

Top News Decliners

8/13 Oncolytics Biotech(R) Announces Public Offering of Common Shares and Warrants -34.0%

11/5 Oncolytics Biotech(R) to Host Conference Call to Discuss Third Quarter Financial Results and Operational Highlights -21.9%

1/14 Form 6-K ONCOLYTICS BIOTECH INC For: Jan 13 -20.5%

1/1 Oncolytics Biotech, Inc. (NASDAQ: ONCY) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. -18.4%

3/5 Oncolytics Biotech® Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights -17.3%

1/13 Oncolytics Biotech® Provides Recap of Key Opinion Leader Call Highlighting Pelareorep's Unique Ability to Activate the Immune System in Late Stage Multiple Myeloma -16.0%

6/5 Oncolytics Biotech's (ONCY) Co-Development Agreement with Pfizer and Merck KGaA Call (Transcript) [Seeking Alpha] -14.1%

12/6 Oncolytics Biotech(R) Regains Compliance with Nasdaq Minimum Bid Price Requirement -12.3%

3/9 Form SUPPL ONCOLYTICS BIOTECH INC -11.1%

6/5 Oncolytics Biotech (R) Announces Study to Investigate Combination of Pelareorep and Avelumab in Metastatic Breast Cancer in Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer -10.0%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day